Scientists have programmed CAR T cells to home in on brain-specific markers like brevican, enabling highly targeted treatment for glioblastoma and other brain conditions.
Despite being the leading cause of fetal and maternal morbidity worldwide, there is still no treatment for pre-eclampsia. Now, an mRNA treatment for pre-eclampsia that works by restoring abnormal placental blood vessels improved maternal and fetal health in mice.
Researchers at the Cleveland Clinic have discovered definitive proof that the kidney microbiome influences the formation of kidney stones—showing that the urinary tract is not sterile and low levels of bacteria are normal.
Relation will receive a total upfront payment from GSK of $45 million—including an equity investment of $15 million.
A new study shows accelerated aging is a key risk factor for colon polyps, a precursor to colorectal cancer, and suggests targeted early screening for those aging faster than their chronological age.
Understanding the cellular and molecular factors influencing how NSCLC reacts to neoadjuvant immuno-chemotherapy unlocks more personalized treatments.
The research demonstrates that glioblastoma organoids are a powerful tool for understanding how CAR-T therapy impacts brain tumors.
A new study has identified two distinct subtypes of metabolic dysfunction-associated steatotic liver disease (MASLD). The discovery could lead to improved diagnosis and treatment.
Results from a study presented at the ASH Annual Meeting showed three-year overall survival rates for people in remission with MCL. The study showed those who were treated with rituximab alone versus immunotherapy and a stem cell transplant were very similar.
A study looked at how prevention, screening, and treatment impacted the death rate from colorectal, lung, breast, cervical, and prostate cancer from 1975–2020.
